Becton, Dickinson & Co.

$253.20

+8.17 (+0.08%) Today
1 Day1D

5 Days5D

1 Month1M

6 Months6M

YTDYTD

1 Year1Y

2 Years2Y

5 Years5Y

MaxMax

About

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

CEO

Thomas E. Polen

Employees

70093

Headquarters

1 Becton Drive Franklin Lakes, NJ, 07417-1880

Founded

1897

Market Cap

Becton, Dickinson & Co. News

Georgia mayor wants BD sterilization plant shuttered for now Oct 17, 2019

The mayor of Covington, Ga. has asked Becton Dickinson (NYSE:BDX) to temporarily shut down a plant there following a weeklong leak of the gas it uses to sterilize medical devices. A letter from Mayor Ronnie Johnston says that independent air quality tests performed for the city from Sept. 17 to Sept. 24 revealed “particularly high levels of […]

The 20 largest medical device companies in the world Sep 17, 2019

Consolidations continue to transform the roster of largest medical device companies in the world — as evidenced by Medical Design & Outsourcing‘s latest Big 100 list. Overall, Big 100 companies saw $397.5 billion in sales during their most recent fiscal years, up 3.5% from the previous year. As companies continue to combine, smaller companies are…

FDA approves BD’s Venovo venous stent Mar 14, 2019

Becton Dickinson & Co. (NYSE:BDX) said today that the FDA granted pre-market approval for its Venovo stent for treating iliofemoral venous occlusive disease. Franklin Lakes, N.J.-based BD touted Venovo as the first on the U.S. market approved to treat obstructed blood flow in the iliac and femoral veins. “The FDA pre-market approval of the Venovo venous […]

BD’s Bard pulls all pelvic mesh products from EU market Mar 07, 2019

Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard is removing its women’s pelvic organ prolapse and stress urinary incontinence mesh devices from the European Market, according to a recently posted field corrective action from the company. The Murray Hill, N.J.-based company said that it is “initiating a cease in production and distribution of these devices and a […]

Becton Dickinson wins FDA 510(k) for Wavelinq 4F endoAVF system Feb 13, 2019

Becton Dickinson (NYSE:BDX) said today that it won FDA 510(k) clearance for its WavelinQ 4 French endovascular arteriovenous fistula creation system. The Franklin Lakes, N.J.-based company said that the newly cleared WavelinQ 4F endoAVF system features improved technology that allows for the creation of an AVF in either the ulnar artery and ulnar vein or the radial […]